Last reviewed · How we verify

NCT06177210

Type 2 Diabetes Remission

Active, enrolled Last updated 6 February 2025
What this trial tests

trial in Type 2 Diabetes Mellitus Remission in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 June 2022
Primary endpoint
30 August 2025
30 August 2025

Quick facts

Lead sponsorUniversity of British Columbia
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment20
Start date1 June 2022
Primary completion30 August 2025
Estimated completion30 August 2025
Sites1 location across Canada

Conditions studied

Sponsor

University of British Columbia

Who can join

19 and older, any sex, with Type 2 Diabetes Mellitus Remission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to establish a cohort of patients with type 2 diabetes (T2D) who have achieved remission through lifestyle intervention or bariatric surgery. Remission is defined as a return of HbA1c to less than 6.5% that occurs spontaneously or following an intervention and in the absence of usual glucose-lowering pharmacotherapy for at least 3 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06177210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing